Abstract
A series of thienylchalcones with fluoro and trifluoromethyl derivatives were synthesized and evaluated for their capability to inhibit human monoamine oxidase A and B. The chemical structures of the compounds have been ascertained by means of their 1HNMR, 13CNMR, mass spectroscopic data and elemental analysis. The results documented that these compounds revealed moderate to good inhibitory activities towards MAO-B than MAO-A. The most active compound, (2E)-1-(thiophen-2-yl)-3-[4-(trifluoromethyl) phenyl] prop-2-en-1-one exhibited with Ki value for MAO-B of 0.90 ± 0.05 µM with a 5-fold selectivity for MAO-B over the MAO-A isoform. All the fluorinated thienylchalcones under the present study showed as reversible inhibitors, while kinetic analysis revealed a competitive mode of binding. Molecular docking studies were executed to further explain the in vitro results of the new compounds, and to establish the hypothetical binding poses for the compounds inside the inhibitor binding cavity of hMAO-B.
Keywords: 2-Acetyl thiophene, docking, MAO-B, reversible inhibition, thienylchalcones.
Graphical Abstract
Letters in Organic Chemistry
Title:Development of Fluorinated Thienylchalcones as Monoamine Oxidase-B Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Docking Studies
Volume: 12 Issue: 9
Author(s): Bijo Mathew, Gulberk Ucar, Samiye Yabanogclu-Ciftci, Ipek Baysal, Jerad Suresh, Githa Elizabeth Mathew, Jobin Kunjumon Vilapurathu, A. M. Nadeena, P. Nabeela, V. Lakshmi, Abitha Haridas and Fajeelath Fathima
Affiliation:
Keywords: 2-Acetyl thiophene, docking, MAO-B, reversible inhibition, thienylchalcones.
Abstract: A series of thienylchalcones with fluoro and trifluoromethyl derivatives were synthesized and evaluated for their capability to inhibit human monoamine oxidase A and B. The chemical structures of the compounds have been ascertained by means of their 1HNMR, 13CNMR, mass spectroscopic data and elemental analysis. The results documented that these compounds revealed moderate to good inhibitory activities towards MAO-B than MAO-A. The most active compound, (2E)-1-(thiophen-2-yl)-3-[4-(trifluoromethyl) phenyl] prop-2-en-1-one exhibited with Ki value for MAO-B of 0.90 ± 0.05 µM with a 5-fold selectivity for MAO-B over the MAO-A isoform. All the fluorinated thienylchalcones under the present study showed as reversible inhibitors, while kinetic analysis revealed a competitive mode of binding. Molecular docking studies were executed to further explain the in vitro results of the new compounds, and to establish the hypothetical binding poses for the compounds inside the inhibitor binding cavity of hMAO-B.
Export Options
About this article
Cite this article as:
Mathew Bijo, Ucar Gulberk, Yabanogclu-Ciftci Samiye, Baysal Ipek, Suresh Jerad, Mathew Elizabeth Githa, Vilapurathu Kunjumon Jobin, Nadeena A. M., Nabeela P., Lakshmi V., Haridas Abitha and Fathima Fajeelath, Development of Fluorinated Thienylchalcones as Monoamine Oxidase-B Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Docking Studies, Letters in Organic Chemistry 2015; 12 (9) . https://dx.doi.org/10.2174/1570178612666150903213416
DOI https://dx.doi.org/10.2174/1570178612666150903213416 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Medicinal Chemistry Methodologies Related to Computational Models in View of Developing Anti-Alzheimer Drugs: An Overview
Current Drug Discovery Technologies The Endocannabinoid/Endovanilloid System and Depression
Current Neuropharmacology Modulation of Response to Audiovisual Stimuli Presented Peripherally by Visually Cued Endogenous Temporal Attention: An Event-Related Potentials Study
Neuroscience and Biomedical Engineering (Discontinued) Enhanced Butyrylcholinesterase Activity may be the Common Link in Triggering Low-Grade Systemic Inflammation and Decrease in Cognitive Function in Diabetes Mellitus and Alzheimers disease
Current Nutrition & Food Science AIDS Vaccines and Reproductive Immunology
Current Immunology Reviews (Discontinued) Editorial: Advances in Psychopharmacological Treatment
Current Drug Targets Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Current Neuropharmacology Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews Herbal Nano Formulations: Patent and Regulatory Overview
Applied Clinical Research, Clinical Trials and Regulatory Affairs Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology Fullerenes in Medicinal Chemistry and their Biological Applications
Mini-Reviews in Medicinal Chemistry Point of Care Cardiac Ultrasound Applications in the Emergency Department and Intensive Care Unit - A Review
Current Cardiology Reviews Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update
CNS & Neurological Disorders - Drug Targets Integrating Autism Spectrum Disorder Pathophysiology: Mitochondria, Vitamin A, CD38, Oxytocin, Serotonin and Melatonergic Alterations in the Placenta and Gut
Current Pharmaceutical Design Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology The Effects of Maternally Administered Methadone, Buprenorphine and Naltrexone on Offspring: Review of Human and Animal Data
Current Neuropharmacology 5-HT3 Receptors: A Potential Therapeutic Target for Epilepsy
Current Neuropharmacology Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry